drugset / Trial / NCT00631813

Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation

NCT00631813

Phase 2 Completed 253 enrolled Movetis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine which dose of prucalopride is safe and effective in patients with chronic constipation. Hypothesis: Prucalopride 1 and 2 mg bid are safe and effective for the treatment of chronic constipation whereas 0,5 mg is a suboptimal dose.

Timeline

Start
1995-11
Primary completion
1997-04
Completion
1997-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prucalopride Small molecule 0.5 mg
Comparator Prucalopride Small molecule 1 mg
Comparator Prucalopride Small molecule 2 mg

Indications